About
Cloudpharm is a bio-pharmaceutical R&D SME founded in 2016 and established in Greece. We specialize in designing digital platforms with a positive impact on healthcare and the green transiton. We focus on drug discovery, hit-to-lead optimization and drug ecotoxicology testing by integrating AI/ML into computational chemistry know-how: virtual screening, molecular dynamics and QSAR/QSTR pipelines for the identification of safe bioactive compounds. We also develop integrated biomedical platforms for natural product informatics. We provide CRO activities as well as royalties for our developed platforms. We are also continuously looking for opportuities to colaborate with consortia on competitive R&D proposals.
Cluster 1: Health
HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate changeHORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate changeHORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potentialHORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from FlavivirusesHORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga virusesHORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobialsHORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative diseasesHORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medicationsHORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseasesHORIZON-HLTH-2027-03-TOOL-08: Towards Artificial General Intelligence (AGI) for healthcareHORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals